Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum GlobeNewswire - Fri Feb 27, 7:30AM CST

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed...

RNXT : 0.8830 (+2.08%)
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting GlobeNewswire - Thu Feb 26, 7:30AM CST

MOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.8830 (+2.08%)
RenovoRx Establishes RenovoCath® Medical Advisory Board GlobeNewswire - Tue Feb 10, 7:30AM CST

MOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.8830 (+2.08%)
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer GlobeNewswire - Thu Feb 5, 7:30AM CST

MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.8830 (+2.08%)
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting GlobeNewswire - Wed Feb 4, 7:30AM CST

MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.8830 (+2.08%)
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting GlobeNewswire - Wed Jan 28, 7:30AM CST

MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.8830 (+2.08%)
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center GlobeNewswire - Tue Jan 20, 7:30AM CST

MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies,...

RNXT : 0.8830 (+2.08%)
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 GlobeNewswire - Wed Jan 14, 7:30AM CST

MOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT)  (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.8830 (+2.08%)
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 GlobeNewswire - Thu Jan 8, 7:30AM CST

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows...

RNXT : 0.8830 (+2.08%)
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 GlobeNewswire - Thu Dec 11, 2025

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.8830 (+2.08%)

Barchart Exclusives

Steer Clear of Dividend ETFs: Why Dividend Stocks Are Better Bought Individually Barchart - Fri Feb 27, 3:32PM CST
Dividend investing has never been more popular, or more misunderstood. Here's why investors should look at dividend ETFs only for research purposes. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot